Back to Search
Start Over
Four-year minimum follow-up of ongoing patients (pts) with chronic-phase chronic myeloid leukemia (CP-CML) in a phase 1 trial of ponatinib (PON)
- Source :
- Journal of Clinical Oncology. 33:7047-7047
- Publication Year :
- 2015
- Publisher :
- American Society of Clinical Oncology (ASCO), 2015.
-
Abstract
- 7047 Background: PON, an approved oral tyrosine kinase inhibitor (TKI), has potent activity against native BCR-ABL and resistant mutants, including T315I. A phase 1 trial evaluated PON safety and a...
Details
- ISSN :
- 15277755 and 0732183X
- Volume :
- 33
- Database :
- OpenAIRE
- Journal :
- Journal of Clinical Oncology
- Accession number :
- edsair.doi...........39583a6c55934c8ac62cf602f0560276
- Full Text :
- https://doi.org/10.1200/jco.2015.33.15_suppl.7047